论文部分内容阅读
目的研究温阳活血方及丹参对硬皮病小鼠模型的影响。方法将温阳活血方及丹参应用于博来霉素诱导的硬皮病小鼠模型。用药小鼠分成早期给药组和硬化后给药组。两组分别分为口饲温阳活血方组、口饲丹参组和静脉注射丹参组。于用药后不同时期进行皮肤、肺组织病理学及血清自身抗体检测分析。结果与未用药的同期对照组相比,硬化后给药组至给药第5周末皮肤组织学无明显改善。早期给药组给药第5周末亦无组织学上的明显改善;第8周末,皮肤厚度比同期对照组有所降低,胶原纤维增生则有较明显改善,尤其是口饲温阳活血方组和静脉注射丹参组(P均<0.05)。肺组织学和血清自身抗体检测提示,硬化后给药和早期给药组均无明显改善。结论早期给药组小鼠随用药时间的递增,皮肤硬化得到明显改善,其中义以口饲温阳活血方组、静脉注射丹参组改善效果更明显;硬化后给药组小鼠皮肤硬化改善不明显。各组小鼠肺纤维化和血清自身抗体均无明显改善。
Objective To investigate the effects of Wenyang Huoxue Fang and Salvia Miltiorrhiza on the mouse model of scleroderma. Methods Wenyang Huoxue Fang and Salvia miltiorrhiza Bunge were applied to the bleomycin-induced scleroderma mouse model. Administration mice were divided into an early administration group and a post-hardening administration group. The two groups were divided into oral feeding Wenyang Huoxue Fang group, oral feeding Danshen group and intravenous injection Danshen group. Skin and lung histopathology and serum autoantibody detection analysis were performed at different times after administration. Results Compared with the non-medicated control group, no significant improvement in skin histology was observed in the post-hardening group and the 5th week after administration. In the early administration group, there was no significant histological improvement at the 5th weekend; on the 8th weekend, the thickness of the skin was lower than that of the control group at the same time, and the collagen fiber hyperplasia was significantly improved, especially for the oral feeding of Wenyang Huoxue Fang group. And intravenous injection of Salvia miltiorrhiza group (P all <0.05). Pulmonary histology and serum autoantibody testing showed no significant improvement in both the post-hardening and early-administered groups. Conclusion In the early administration group mice, the skin hardening is significantly improved with the increase of the administration time. The improvement effects of Yiyi Oral-feeding Wenyang Huoxue Decoction group and intravenous injection of Salvia miltiorrhiza group are more obvious; obvious. There was no significant improvement in pulmonary fibrosis and serum autoantibodies in all groups.